Venous thromboembolism (VTE) is the third most common cardiovascular disease. For most
patients, the standard of treatment has long consisted on low-molecular-weight heparin …

Introduction Acute venous thromboembolism (VTE) is a common disease associated to
significant morbidity and mortality. Materials and methods We systematically reviewed and …

For decades the antithrombotic management of venous thromboembolism (VTE) was limited
to parenteral heparin formulations and oral vitamin K antagonists. Even though both classes …

Pulmonary embolism (PE) is a relatively common cardiovascular emergency. PE and deep
vein thrombosis (DVT) are considered expressions of the same disease, termed as venous …

Objective: The objective of this review is to examine the management strategies for
pulmonary embolism (PE) with an emphasis of the role of direct oral anticoagulants …

The treatment of acute venous thromboembolism (VTE) is being completely modified with
the development of direct oral anticoagulants (DOACs). Rivaroxaban, apixaban and …

Non-structured Abstract: Direct Oral Anticoagulants (DOACs) have become the preferred
option for treatment of Venous Thromboembolism (VTE) due to their favorable profile …

As a result of the successful completion of their respective phase III studies compared with
vitamin K antagonists (VKAs), four direct oral anticoagulants (DOACs) have been approved …

Venous thromboembolism (VTE) is a leading cause of morbidity and mortality worldwide.
For decades, low molecular weight heparins (LMWH) and vitamin K-antagonists have been …

Anticoagulant therapy is the cornerstone of therapeutic management in acute venous
thromboembolism (VTE), consisting of pulmonary embolism and deep vein thrombosis …